Meeting
2022 ASCO Annual Meeting
Clinical and patient (pt)-reported outcomes (PROs) in a phase 3, randomized, open-label study evaluating axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in elderly pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL; ZUMA-7).
Authors
Jason Westin
University of Texas MD Anderson Cancer Center, Houston, TX
Jason Westin , Frederick L. Locke , Michael Dickinson , Armin Ghobadi , Mahmoud Elsawy , Tom van Meerten , David Bernard Miklos , Matthew Ulrickson , Miguel-Angel Perales , Umar Farooq , Luciano Wannesson , Lori Ann Leslie , Marie José Kersten , Caron Alyce Jacobson , John M. Pagel , Gerald Wulf , Linqiu Du , Julia Snider , Christina Ann To , Olalekan O. Oluwole
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT03391466
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7548)
DOI
10.1200/JCO.2022.40.16_suppl.7548
Abstract #
7548
Poster Bd #
201
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma.
First Author: Jason Westin
Poster
2020 ASCO Virtual Scientific Program
Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.
First Author: Frederick Lundry Locke
Poster
2019 ASCO Annual Meeting
ZUMA-12: A phase 2 multicenter study of axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients (pts) with high-risk large B cell lymphoma (LBCL).
First Author: Sattva Swarup Neelapu
Poster
2014 ASCO Annual Meeting
Multicenter, phase III, open-label, randomized study in relapsed/refractory CLL to evaluate the benefit of GDC-0199 (ABT-199) plus rituximab compared with bendamustine plus rituximab.
First Author: Mehrdad Mobasher